ProfileGDS5678 / 1430216_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 63% 63% 63% 63% 64% 63% 62% 63% 63% 64% 63% 63% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0062666
GSM967853U87-EV human glioblastoma xenograft - Control 23.7820663
GSM967854U87-EV human glioblastoma xenograft - Control 33.785163
GSM967855U87-EV human glioblastoma xenograft - Control 43.7199463
GSM967856U87-EV human glioblastoma xenograft - Control 53.7246963
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8996964
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8240263
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7290562
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7575963
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7711563
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8638564
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7467163
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7667663
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7728763